Barclays analyst Peter Lawson downgraded ImmunoGen to Equal Weight from Overweight with a price target of $31, up from $27. The analyst cites the announced acquisition of ImmunoGen by AbbVie for the downgrade. The firm sees a high likelihood of deal closure on time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMGN:
- ImmunoGen downgraded to Equal Weight from Overweight at Barclays
- ImmunoGen downgraded to Hold from Buy at Jefferies
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- ImmunoGen downgraded to Neutral from Buy at Guggenheim
- ImmunoGen downgraded to Market Perform from Outperform at BMO Capital